Press release from PR Newswire
ViroPharma To Participate In Several June Healthcare Investor Conferences
Friday, May 31, 2013
ViroPharma To Participate In Several June Healthcare Investor Conferences14:00 EDT Friday, May 31, 2013
EXTON, Pa., May 31, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Jefferies 2013 Healthcare Conference at 9:30 AM ET on Wednesday June 5, 2013. The conference is being held in New York City.
ViroPharma also announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Goldman Sachs 34th Annual Global Healthcare Conference at 4:00 PM PT (7:00 PM ET) on Tuesday, June 11, 2013. The conference is being held in Rancho Palos Verdes, CA.
Mr. Milano also will be presenting at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 2:20 PM ET on Tuesday, June 18, 2013. The conference is being held in Boston, MA.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
For further information: Robert A. Doody Jr., Assistant Director, Investor Relations, (610) 321-6290